7ZA Stock Chart & Stats
€0.29
>-€0.01(-1.21%)
At close: 4:00 PM EST
€0.29
>-€0.01(-1.21%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.46
Previous CloseN/A
Volume0.00
Average Volume (3M)519.00
Market Cap
€7.55M
Enterprise Value€352.94
Total Cash (Recent Filing)€38.05M
Total Debt (Recent Filing)€490.00K
Price to Earnings (P/E)―
Beta52.85
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding133,535,460
10 Day Avg. Volume0
30 Day Avg. Volume519
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€4.76M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces solvency pressure and interest obligations, preserving financial flexibility while the company funds late-stage development and prepares for potential commercialization.
Loss Trajectory ImprovingImproving losses indicate some progress in cost control or development execution. Although profitability remains distant, a less negative earnings trajectory can reduce the pace of capital consumption over time.
Orphan Specialty Medicine FocusA focused orphan and hospital-medicine strategy can support differentiated positioning and specialist adoption. Orviglance addresses a defined imaging need where standard gadolinium agents may be unsuitable.
Bears Say
Pre-revenue Business ModelThe absence of revenue means the company has not yet demonstrated commercial demand or operating leverage. Continued dependence on product development success leaves fundamentals exposed to execution and approval risk.
Sustained Cash BurnPersistent negative operating and free cash flow indicates that operations cannot currently fund development. Unless revenues arrive, the company may need additional external capital, creating funding and dilution risk.
Eroding Capital BaseOngoing losses are reducing shareholders’ equity and weakening the balance-sheet cushion. This limits resilience if development costs remain elevated or commercialization takes longer than expected.
Ascelia Pharma AB News
7ZA FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was <€0.01 and its highest was €0.46 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is €7.55M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 64 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on Aug 20, 2026. The company reported -€0.008 earnings per share for the quarter.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 133,535,460 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -€0.008 in its last earnings report. Following the earnings report the stock price went down -6.818%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in DE:7ZA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
OncoZenge AB
―
Immunicum AB
―
Cantargia AB
―